GlassScriptPhysician profile
George C Gilbert
NPI 1215021100
$6,274.64
in general payments reported to CMS, 2019-2025
56 companies · $59.54 in 2025
The $59.54 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,159 · 2020: $1,088 · 2021: $1,547 · 2022: $1,414 · 2023: $574 · 2024: $432 · 2025: $59.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,066.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $567.11 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $555.71 | 2019-2022 | |
| Orexo US, INC. | $522.32 | 2019-2024 | Zubsolv |
| Novartis Pharmaceuticals Corporation | $507.53 | 2019-2024 | |
| Abbvie INC. | $375.52 | 2019-2023 | |
| Gilead Sciences, INC. | $336.78 | 2019-2022 | |
| Amgen INC. | $305.08 | 2019-2024 | Otezla, Repatha, Evenity |
| Sanofi-Aventis U.S. LLC | $278.09 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $191.82 | 2021-2024 | |
| Amarin Pharma, INC. | $190.27 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $176.23 | 2019-2023 | Trulance, Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $160.79 | 2019-2023 | Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $151.53 | 2022 | |
| Dexcom, INC. | $147.67 | 2021-2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $144.87 | 2019-2021 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.